Virtu Financial LLC Rigel Pharmaceuticals Inc Transaction History

Virtu Financial LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 27, 2023	BUY	$1.12 - $1.82 $56,322 - $91,524	50,288 New	50,288 $65,000
Q2 2022 Aug 09, 2022	BUY	$0.67 - $3.19 $164,302 - $782,274	245,227 New	245,227 $277,000
Q2 2021 Sep 17, 2021	SELL	$3.09 - $4.54 $118,838 - $174,603	-38,459 Closed	0 $0
Q1 2021 May 19, 2021	BUY	$3.35 - $4.93 $128,837 - $189,602	38,459 New	38,459 $132,000
Q4 2020 Feb 24, 2021	SELL	$2.35 - $3.74 $107,244 - $170,678	-45,636 Closed	0 $0
Q3 2020 Dec 11, 2020	BUY	$1.78 - $4.13 $16,192 - $37,570	9,097 Added 24.9%	45,636 $110,000
Q2 2020 Aug 07, 2020	BUY	$1.41 - $2.05 $51,519 - $74,904	36,539 New	36,539 $67,000
Q3 2019 Nov 20, 2019	SELL	$1.63 - $2.62 $42,050 - $67,590	-25,798 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$2.02 - $2.61 $15,572 - $20,120	7,709 Added 42.62%	25,798 $67,000
Q1 2019 Apr 12, 2019	SELL	$2.0 - $2.65 $94,182 - $124,791	-47,091 Reduced 72.25%	18,089 $46,000
Q4 2018 Jan 16, 2019	SELL	$2.08 - $3.36 $75,778 - $122,411	-36,432 Reduced 35.85%	65,180 $150,000
Q3 2018 Nov 13, 2018	BUY	$2.6 - $3.59 $264,191 - $364,787	101,612 New	101,612 $326,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.